Patents Examined by Jeffrey S. Parkin
  • Patent number: 10053496
    Abstract: The present application relates to methods of producing exosomes. The application also provides a method for preparing a protein composition comprising culturing an exosome-producing cell expressing a Nef-fusion protein comprising a Nef-derived peptide fused to a protein of interest; isolating exosomes from the exosome-producing cell culture; and purifying the protein of interest from the isolated exosomes. The application further discloses compositions that comprise exosomes containing the Nef-fusion protein, as well as methods of using the Nef-fusion protein and exosomes containing the Nef-fusion protein.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: August 21, 2018
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Vincent Craig Bond, Michael Powell, Ming Bo Huang, Syed Ali
  • Patent number: 9175077
    Abstract: The invention relates to nucleotides encoding therapeutic polypeptides and fragments thereof isolated from beta-human chorionic gonadotropin (?-hCG) found in human early pregnancy urine, now synthetically produced and designated Maternin. The therapeutic polypeptides and their functional equivalents are useful in treating and/or preventing various medical conditions. Examples of therapeutic effects of the therapeutic polypeptides include anti-HIV, anti-cancer, anti-wasting, prohematopoietic (e.g., anemias, radiation-mediated bone marrow damage, and trauma-mediated blood loss), and anti-angiogenic effects. The invention also provides pharmaceutical compositions comprising the therapeutic polypeptides, as well as methods for using the therapeutic polypeptides, functional equivalents and/or pharmaceutical compositions in the treatment and/or prevention of such medical conditions.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: November 3, 2015
    Assignee: NOBEL BIOSCIENCES LLC
    Inventors: Robert C. Gallo, Joseph Bryant, Yanto Lunardi-Iskandar
  • Patent number: 9011875
    Abstract: The present invention relates to mosaic HIV-1 group M Gag sequences and to a composition comprising same.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: April 21, 2015
    Assignees: Los Alamos National Security, LLC, Beth Israel Deaconess Medical Center, Duke University, The University of Alabama at Birmingham Research Foundation
    Inventors: Bette T. Korber, Simon Perkins, Tanmoy Bhattacharya, William M. Fischer, James Theiler, Norman Letvin, Barton F. Haynes, Beatrice H. Hahn, Karina Yusim, Carla Kuiken
  • Patent number: 8865876
    Abstract: Engineered lectins and methods of using such reagents for both preventing and treating a broad array of viral infections are provided. The lectins of the invention are engineered in two ways, first through the enhancement of the natural mode of action of lectins against viruses through linked multimerization, and second through the creation of a new class of reagents, hereinafter referred to as a “lectibody” or “lectibodies”, that engage host immune function in addition to simply binding glycosylated viral proteins via the combination of a lectin and the Fc region of an antibody in order to drive Fc-mediated effector functions including ADCC (antibody-dependent cell-mediated cytotoxicity), increased half-life, complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated phagocytosis (ADCP) in response to a lectin-mediated carbohydrate-binding event.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: October 21, 2014
    Assignee: California Institute of Technology
    Inventors: Stephen L. Mayo, Jennifer Keeffe, Alex L. Perryman
  • Patent number: 8858946
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.
    Type: Grant
    Filed: July 24, 2008
    Date of Patent: October 14, 2014
    Assignees: The University of Iowa Research Foundation, The United States of America, as represented by the Secretary of the Department of Veterans Affairs
    Inventors: Jack T. Stapleton, Jinhua Xiang, Donna Klinzman, James H. McLinden
  • Patent number: 8840890
    Abstract: The present application provides methods for producing human monoclonal antibodies without using hybridoma technology, antibodies produced used the described methods, and methods for using the antibodies to treat or prevent disease conditions (e.g., infection by pathogens such as the Human Immunodeficiency Virus).
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: September 23, 2014
    Assignee: University of Maryland, Baltimore
    Inventors: George K. Lewis, Yongjun Guan
  • Patent number: 8841068
    Abstract: The present invention provides compositions and methods related to determining the severity of viral infections and identifying antiviral agents. In certain embodiments, the invention comprises determining the expression level of APOBEC-1 related proteins, where the expression level of APOBEC-1 related proteins is an indicator for disease severity and/or effectiveness of a potential antiviral agent. In one embodiment, the present invention provides for a method of screening for an antiviral agent.
    Type: Grant
    Filed: February 13, 2006
    Date of Patent: September 23, 2014
    Assignee: University of Rochester
    Inventors: Harold C. Smith, Xia Jin, Andrew Brooks
  • Patent number: 8795682
    Abstract: Embodiments of the present disclosure encompasses virus-like particles, methods of making virus-like particles, including expression vectors, wherein the virus-like particles may comprise enhanced levels of capsid-bound a chimeric HN-Env polypeptide compared to VLPs derived from unmodified HIV-env polypeptides. Embodiments of the virus-like particle may have Env-specific epitopes exposed on the outer surface thereof. In one embodiment, the Env-specific epitopes exposed on the outer surface of the virus-like particle may specifically bind with an anti-HIV-Env specific antibody. Embodiments of the disclosure further includes methods of generating an antibody specific to an epitope of an HIV-Env polypeptide, comprising delivering to an animal or a human an effective amount of a suspension of virus-like particles comprising a chimeric HIV-Eny polypeptide, thereby inducing the formation of an antibody specific to an epitope of an HIV-1 eny polypeptide.
    Type: Grant
    Filed: May 2, 2008
    Date of Patent: August 5, 2014
    Assignees: Emory University, The UAB Research Foundation, Novavax, Inc.
    Inventors: Richard W. Compans, Baozhong Wang, Beatrice Hahn, Weimin Liu, Gale Smith, Peter Pushko
  • Patent number: 8795687
    Abstract: The present invention provides virus-like particles (VLP) highly secreting or producing signal peptide obtained by altering a signal sequence derived from West Nile virus (WNV), the signal peptide, a WNV VLP secretion expression vector containing a nucleic acid encoding prM protein and E protein, a WNP VLP highly secreting or producing animal cell line harboring the vector, a WNV vaccine containing WNV VLP obtained by the cell line as an active ingredient, and a WNV DNA vaccine containing the VLP secretion expression vector as an active ingredient.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: August 5, 2014
    Assignees: Japan as Represented by the Director-General of National Institute of Infections Diseases, The Research Foundation for Microbial Diseases of Osaka University
    Inventors: Asato Kojima, Hidehiro Takahashi, Toyokazu Ishikawa
  • Patent number: 8747862
    Abstract: The claimed invention is directed toward an HIV-2 isolate designated NWK08F, including variants, and isolated proteins and nucleotides obtained from said isolates.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: June 10, 2014
    Assignee: Tulane University Health Sciences Center
    Inventors: Stephen M. Smith, Preston A. Marx
  • Patent number: 8680244
    Abstract: Enveloped virus vectors are described which comprise a cellular virus receptor protein and which are capable of fusing with a cell which comprises a viral envelope protein to which the cellular virus receptor protein is cognate. Enveloped virus vectors comprising a plurality of cellular virus receptor proteins are also described. Methods for making the enveloped virus vectors are described, as are methods of using the enveloped virus vectors. The invention further relates to a lipoparticle comprising a membrane spanning protein, and the lipoparticle can be attached to a sensor surface. The invention relates to methods of producing and using the lipoparticle to, inter alia, assess protein binding interactions.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: March 25, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Robert Doms, Joseph Rucker, Trevor L Hoffman, Paul Bates, James A Hoxie, Michael J Endres, John Balliet, Dennis L Kolson
  • Patent number: 8673307
    Abstract: Broad neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV, especially the preparation and use of highly neutralizing antibodies directed to HIV gp120 envelope protein, in the vaccination and treatment of HIV-infected patients.
    Type: Grant
    Filed: March 8, 2010
    Date of Patent: March 18, 2014
    Assignee: The Rockefeller University
    Inventors: Michel C. Nussenzweig, Johannes Scheid, John Pietzsch
  • Patent number: 8637044
    Abstract: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: January 28, 2014
    Assignee: Novartis AG
    Inventors: Susan Barnett, Rino Rappuoli, Victoria A Sharma, Indresh K Srivastava, Jan Zur Megede
  • Patent number: 8632782
    Abstract: The invention features novel attenuated dengue virus mutants and compositions thereof.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: January 21, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Patent number: 8628782
    Abstract: Disclosed herein are isolated immunogens including variant gp120 polypeptides. In an example, a variant gp120 polypeptide includes a deletion of at least 8 consecutive residues of the fourth conserved loop (C4) between residues 419 and 434 of gp120 according to HXB2 numbering. Also provided are isolated nucleic acid molecules encoding the disclosed isolated immunogens. In an example, an isolated nucleic acid molecule further includes a nucleic acid molecule encoding a hepatitis B surface antigen or a variant thereof. Compositions including the isolated immunogens including variant gp120 polypeptides are also disclosed. In some examples, a composition further includes a carrier protein, such as a hepatitis B surface antigen or a variant thereof (natural or recombinant). Viral-like particles are also provided including any of the disclosed isolated immunogens or compositions.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: January 14, 2014
    Assignee: The United States of America, as Represented by the Department of Health and Human Services
    Inventor: Ira Berkower
  • Patent number: 8609100
    Abstract: A cell surface molecule designated DCIR (for dendritic cells ImmunoReceptor), a member of a recently described family of DC-expressing C-type lectin receptors, has been shown to participate to the capture of human immunodeficiency virus (HIV) and promote infection in trans and in cis of autologous CD4(+) T cells from human immature monocyte-derived DC. The contribution of DCIR to these processes was revealed using DCIR-specific siRNAs and a polyclonal antibody specific for the carbohydrate recognition domain of DCIR. Therapeutic agents for HIV infection are therefore provided herein. These therapeutic agents are useful for impairing the interaction between DCIR and HIV and as such may be useful for treatment or prevention of HIV infection. Also provided are assays for identifying additional therapeutics agents for treatment or prevention HIV infection.
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: December 17, 2013
    Assignee: Universite Laval
    Inventors: Alexandra Lambert, Caroline Gilbert, Michel J. Tremblay
  • Patent number: 8603490
    Abstract: The invention provides methods and compositions for raising an immune response in a subject by administering an HIV antigen. The HIV antigens include HIV clade C polynucleotides and polypeptides. The invention also provides for recombinant HIV viral particles and compositions.
    Type: Grant
    Filed: September 29, 2008
    Date of Patent: December 10, 2013
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventor: Ruth M. Ruprecht
  • Patent number: RE45016
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: July 15, 2014
    Assignee: The United States of America, as represented by the Secretary of the Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Patent number: RE45053
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: July 29, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Patent number: RE45123
    Abstract: The invention provides compositions featuring an attenuated dengue virus mutant or an attenuated chimeric dengue virus mutant.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: September 9, 2014
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai